Evidence map›Paper›PMID 34834275›Full record

ArticlePharmaceutics2021

Cationic and Biocompatible Polymer/Lipid Nanoparticles as Immunoadjuvants.

Yunys Pérez-Betancourt, Péricles Marques Araujo, Bianca de Carvalho Lins Fernandes Távora, Daniele Rodrigues Pereira, Eliana Lima Faquim-Mauro, Ana Maria Carmona-Ribeiro

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Emerging Cationic Nanovaccines.Pharmaceutics · 2024
    Review
  5. Article
  6. Review
  7. Supramolecular Nanostructures for Vaccines.Biomimetics (Basel, Switzerland) · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Yunys Pérez-BetancourtBiocolloids Laboratory, Departamento de Bioquímica, Instituto de Química, Universidade de São Paulo, Avenida Professor Lineu Prestes, 748 Butantan, São Paulo 05508-000, Brazil.ORCID 0000-0003-4998-5173
Péricles Marques AraujoBiocolloids Laboratory, Departamento de Bioquímica, Instituto de Química, Universidade de São Paulo, Avenida Professor Lineu Prestes, 748 Butantan, São Paulo 05508-000, Brazil.
Bianca de Carvalho Lins Fernandes TávoraImmunopathology Laboratory, Butantan Institute, Avenida Vital Brasil, 1500 Butantan, São Paulo 05503-900, Brazil.
Daniele Rodrigues PereiraImmunopathology Laboratory, Butantan Institute, Avenida Vital Brasil, 1500 Butantan, São Paulo 05503-900, Brazil.
Eliana Lima Faquim-MauroImmunopathology Laboratory, Butantan Institute, Avenida Vital Brasil, 1500 Butantan, São Paulo 05503-900, Brazil.
Ana Maria Carmona-RibeiroBiocolloids Laboratory, Departamento de Bioquímica, Instituto de Química, Universidade de São Paulo, Avenida Professor Lineu Prestes, 748 Butantan, São Paulo 05508-000, Brazil.ORCID 0000-0001-8500-2707
Universidade de São Paulo · BR

Funding

National Council for Scientific and Technological Development 302352/2014-7National Council for Scientific and Technological Development 302758/2019-4São Paulo Research Foundation 2019/17625-0São Paulo Research Foundation 2019/17685-2
6 · The paper itself

Abstract

Nanostructures have been of paramount importance for developing immunoadjuvants. They must be cationic and non-cytotoxic, easily assembling with usually oppositely charged antigens such as proteins, haptens or nucleic acids for use in vaccines. We obtained optimal hybrid nanoparticles (NPs) from the biocompatible polymer poly(methyl methacrylate) (PMMA) and the cationic lipid dioctadecyl dimethyl ammonium bromide (DODAB) by emulsion polymerization of methyl methacrylate (MMA) in the presence of DODAB. NPs adsorbed ovalbumin (OVA) as a model antigen and we determined their adjuvant properties. Interestingly, they elicited high double immune responses of the cellular and humoral types overcoming the poor biocompatibility of DODAB-based adjuvants of the bilayer type. The results suggested that the novel adjuvant would be possibly of use in a variety of vaccines.

Indexed as

biocompatible polymercationic lipidcytokines profiledelayed type hypersensitivitydioctadecyl dimethyl ammonium bromidedynamic light scatteringhybrid nanoparticlesnanoparticles cytotoxicityovalbuminpoly(methyl methacrylate)

Identifiers

PMID34834275
PMCPMC8621050
OpenAlexW3209327225

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.